Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -23.40% is 43% above its 5-year average of -41.05%, near the high end of its 5-year range (-83.91%–-23.40%).
32.86% above its 12-month average of -34.85%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.48%.
RETURN ON ASSETS (ROA)
-23.40%
RETURN ON ASSETS (ROA) AVG TTM
-34.85%
RETURN ON ASSETS (ROA) AVG 3Y
-33.75%
RETURN ON ASSETS (ROA) AVG 5Y
-41.05%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.86%
CURRENT VS 3Y AVG
+30.67%
CURRENT VS 5Y AVG
+43.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
+19.73%
vs the sector median at left
Climb Bio, Inc.
Market Cap
$624.74M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$633.55M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$611.51M
Return on Assets (ROA)
-13.75%
TTM Avg
-12.94%
3Y Avg
-23.44%
5Y Avg
-17.36%
Market Cap
$643.59M
Return on Assets (ROA)
-15.25%
TTM Avg
-20.29%
3Y Avg
-14.84%
5Y Avg
-12.37%
Market Cap
$603.91M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
Market Cap
$648.52M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$595.08M
Return on Assets (ROA)
45.55%
TTM Avg
3.15%
3Y Avg
-47.64%
5Y Avg
-20.78%
Market Cap
$658.27M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$661.10M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Climb Bio, Inc. (CLYM) | $624.74M | -23.40% | -34.85% | -33.75% | -41.05% |
| Aura Biosciences, Inc. (AURA)vs › | $633.55M | -37.63% | -55.16% | -41.63% | -48.17% |
| AngioDynamics, Inc. (ANGO)vs › | $611.51M | -13.75% | -12.94% | -23.44% | -17.36% |
| OmniAb, Inc. (OABI)vs › | $643.59M | -15.25% | -20.29% | -14.84% | -12.37% |
| Fulgent Genetics, Inc. (FLGT)vs › | $603.91M | -7.75% | -4.25% | -2.93% | 9.76% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $648.52M | -36.37% | -26.71% | -31.04% | -27.33% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $595.08M | 45.55% | 3.15% | -47.64% | -20.78% |
| Helus Pharma Inc. (HELP)vs › | $658.27M | -70.67% | -51.05% | -54.02% | -55.25% |
| Annexon, Inc. (ANNX)vs › | $661.10M | -82.36% | -56.97% | -52.21% | -45.34% |
| MiMedx Group, Inc. (MDXG)vs › | $664.59M | 2.22% | 15.13% | 10.21% | 1.65% |
ROA
-23.4%
ROE
-24.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.68% |
| 2024-12-31 | -34.02% |
| 2023-12-31 | -31.79% |
| 2022-12-31 | -33.52% |
| 2021-12-31 | -27.41% |
| 2020-12-31 | -83.91% |
| 2019-12-31 | -30.60% |
